Variable importance plot (mean decrease accuracy and mean decrease Gini). by Fernando Martinez-Taboada (8655132)

Cox hazard regression model of renalase and primary composite outcome. by Basmah Safdar (12213257)

Decreased production of antiviral factors in patients infected with SARS-CoV-2 due to reduced TLR7 expression by Julia Cataldo Lima (22811497)

“…</p> <p>The virus that causes coronavirus disease 2019 (COVID-19), severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has a way of weakening the body’s early immune defense, called the innate immune system. …”

5-fluorouracil decreases rates of persistent and reappearing actinic keratoses: The VAKCC Trial by Moniyka Sachar (9399032)

Structure of YOLOv5s-SBC. by Zhongjian Xie (4633099)

“…The experimental results showed that P-YOLOv5s-GRNF increased the mAP(mean average precision) by 0.8%, 4.3%, 3.2%, 0.7%, 19.3%, 9.8%, 3.1% compared to mainstream object detection algorithms YOLOv5s, YOLOv6s, YOLOv7-tiny, YOLOv8s, YOLOv5s-Shufflenetv2, YOLOv5s-Mobilenetv3, YOLOv5s-Ghost, respectively. …”

Comparison of ∑PBB, ∑BDE, ∑PCN and ∑DDT concentrations and concentrations of some congeners in eggs analyzed in this study and other relevant studies (ng/g ww, geometric mean and r... by Matti Viluksela (321291)

Evaluation of <i>in vitro</i> activity of LNP-siRNA on LX-2 cells stimulated by 2 ng/mL of TGF-β. by Ying-Chou Chen (263436)

Subjects:

Mean scores and 95% CIs according to SARS-CoV-2 infection status and work-related determinants. by A. H. Ayesha Lavell (16734002)

Subjects:

Preoperative and postoperative questionnaire scores of groups A, B, C, D, E, F, and G. by Régis Cohen (11419436)

Subjects:

DGAT-1 Inhibitor A922500 decreases the pro-inflammatory profile and cell death induced by SARS-CoV-2 infection and reduces the viral load in human monocyte. by Suelen Silva Gomes Dias (9928813)

Preoperative and postoperative scores for the different dimensions of BAROS scores in groups A, B, C D, E, F, and G. by Régis Cohen (11419436)

Subjects:

Study Flow Diagram. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments). by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

Subjects:

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). by Elizabeth S. Munroe (21568166)

Subjects: